CD19-CAR Trials

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Journal

• Publication date

  2014-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PPO.0000000000000031PMID 24667955PMCID PMC3979594
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014influential reference
• Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

  2013cited by this paper
• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

  2013cited by this paper
• Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses With Acceptable Toxicity But Without Chronic B-Cell Aplasia In Children With Relapsed Or Refractory Acute Lymphoblastic Leukemia (ALL) Even After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

  2013cited by this paper
• Clinical Responses In Patients Infused With T Lymphocytes Redirected To Target κ-Light Immunoglobulin Chain

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

  2013cited by this paper
• First Clinical Trials Employing Sleeping Beauty Gene Transfer System and Artificial Antigen Presenting Cells To Generate and Infuse T Cells Expressing CD19-Specific Chimeric Antigen Receptor

  2013cited by this paper
• Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy

  2013cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011influential reference
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• Inducible apoptosis as a safety switch for adoptive cell therapy.

  2011cited by this paper
• Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.

  2010cited by this paper
• Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.

  2010cited by this paper
• Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

  2010cited by this paper
• Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.

  2008cited by this paper
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  2008cited by this paper
• Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

  2007cited by this paper
• T cell immune reconstitution following lymphodepletion.

  2007cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

  2006cited by this paper
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.

  2005cited by this paper
• A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.

  2005cited by this paper
• Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

  2005cited by this paper
• CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells

  2005cited by this paper
• Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia

  2004cited by this paper
• Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15

  2003cited by this paper
• Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.

  2002cited by this paper
• Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.

  1999cited by this paper
• Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes

  1998cited by this paper
• Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product.

  1998cited by this paper
• Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma.

  1997cited by this paper
• CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy.

  1995cited by this paper
• CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes.

  1992cited by this paper

• Tumour priming by ultrasound mechanogenetics for CAR T therapy

  2025cites this paper
• Pig jejunal single-cell RNA landscapes revealing breed-specific immunology differentiation at various domestication stages

  2025cites this paper
• Engineering a Multilayered 3D Stromal Barrier Model for Quantitative Analysis of T Cell Infiltration and Cytotoxicity.

  2025cites this paper
• Chimeric Antigen Receptor-Based Cellular Therapy for T-Cell Malignancies.

  2025cites this paper
• Characterization of Chimeric Antigen Receptor Modified T Cells Expressing scFv-IL-13Rα2 after Radiolabeling with 89Zirconium Oxine for PET Imaging

  2023cites this paper
• Characterization of chimeric antigen receptor modified T cells expressing scFv-IL-13Rα2 after radiolabeling with 89Zirconium oxine for PET imaging

  2023cites this paper
• Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility

  2023cites this paper
• CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma

  2023cites this paper
• Light-responsive nanomedicine for cancer immunotherapy

  2023cites this paper
• Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors

  2022cites this paper
• NR4A1 mediates NK‐cell dysfunction in hepatocellular carcinoma via the IFN‐γ/p‐STAT1/IRF1 pathway

  2022cites this paper
• CAR Therapy for T-cell Malignancies

  2022cites this paper
• Minicircles for CAR T Cell Production by Sleeping Beauty Transposition: A Technological Overview.

  2022cites this paper
• Bioinstructive implantable scaffolds for rapid in vivo manufacture and release of CAR-T cells

  2022cites this paper
• In vitro machine learning-based CAR T immunological synapse quality measurements correlate with patient clinical outcomes

  2022cites this paper
• Robust CAR-T memory formation and function via hematopoietic stem cell delivery

  2021cites this paper
• Treatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells

  2021cites this paper
• Targeting Glioblastoma: The Current State of Different Therapeutic Approaches

  2021cites this paper
• Designed Ankyrin Repeat Protein (DARPin) to target chimeric antigen receptor (CAR)-redirected T cells towards CD4+ T cells to reduce the latent HIV+ cell reservoir

  2020cites this paper
• The Application of CAR-T Cells in Haematological Malignancies

  2020cites this paper
• CAR-T Cell Clinical Trials Experience – Past, Present and Future

  2020cites this paper
• Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies

  2020cites this paper
• A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies

  2020cites this paper
• Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways

  2020cites this paper
• Rapid Assembly and Screening of Multivalent Immune Cell-Redirecting Therapies for Leukemia

  2020cites this paper
• Nanotechnology and Immunoengineering: How nanotechnology can boost CAR-T therapy.

  2020cites this paper
• Engineering light-controllable CAR T cells for cancer immunotherapy

  2020cites this paper
• Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells.

  2020cites this paper
• The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy

  2020cites this paper
• Bioactivity and safety of chimeric switch receptor T cells in glioblastoma patients.

  2019cites this paper
• Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

  2019cites this paper
• Targeting T Cell Malignancies Using CD4CAR T-Cells and Implementing a Natural Safety Switch

  2019cites this paper
• Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures

  2019cites this paper
• Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells

  2018cites this paper
• Reprint of: Virus-Specific T Cells: Broadening Applicability.

  2018cites this paper
• Natural Killer cell subsets in hematological diseases : learning for immunotherapy

  2018cites this paper
• Expansion of allogeneic NK cells with efficient antibody-dependent cell cytotoxicity against multiple tumors

  2018cites this paper
• The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity

  2018cites this paper
• Producing proT cells to promote immunotherapies

  2018cites this paper
• CML Hematopoietic Stem Cells Expressing IL1RAP Can Be Targeted by Chimeric Antigen Receptor-Engineered T Cells.

  2018cites this paper
• IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor

  2018cites this paper
• La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease.

  2018cites this paper
• Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients

  2018cites this paper
• CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells

  2018cites this paper
• Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia

  2018cites this paper
• Animal models for studying tumor microenvironment (TME) and resistance to lymphocytic infiltration

  2018cites this paper
• PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine

  2018cites this paper
• Virus-Specific T Cells: Broadening Applicability.

  2018cites this paper
• Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia

  2018cites this paper
• Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma.

  2018cites this paper
• Biomarkers and therapeutic advances in glioblastoma multiforme

  2018cites this paper
• Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy

  2017cites this paper
• Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors

  2017cites this paper
• Antigen Loss Variants: Catching Hold of Escaping Foes

  2017cites this paper
• Chimeric antigen receptor engineered stem cells: a novel HIV therapy.

  2017cites this paper
• B16 Lung Melanoma Model to Study the Role of Th9 Cells in Cancer.

  2017cites this paper
• Genome variation across cancers scales with tissue stiffness - an invasion-mutation mechanism and implications for immune cell infiltration.

  2017cites this paper
• Natural Killer Cell-Based Cancer Immunotherapies: From Immune Evasion to Promising Targeted Cellular Therapies

  2017cites this paper
• A Transgenic Dual-Luciferase Reporter Mouse for Longitudinal and Functional Monitoring of T Cells In Vivo

  2017cites this paper
• A compound chimeric antigen receptor strategy for targeting multiple myeloma

  2017cites this paper
• Adoptive immunotherapy for B-cell malignancies using CD19-targeted chimeric antigen receptor T-cells: A systematic review of efficacy and safety.

  2017cites this paper
• Leveraging natural killer cells for cancer immunotherapy.

  2017cites this paper
• A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.

  2017cites this paper
• On the way to find a cure: Purging latent HIV‐1 reservoirs

  2017cites this paper
• Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.

  2016cites this paper
• Strategies to Enhance Migration and Persistence of Chimeric Antigen Receptor (CAR)-T Cells into Tumors

  2016cites this paper
• CD 19 chimeric antigen receptor ( CD 19 CAR )-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin ’ s Lymphomas

  2016cites this paper
• Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy.

  2016cites this paper
• Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.

  2016cites this paper
• Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.

  2016cites this paper
• L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice

  2016cites this paper
• Chimeric antigen receptor T-cell therapy for solid tumors

  2016cites this paper
• Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies

  2016cites this paper
• Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells.

  2016cites this paper
• Novel immunotherapies in lymphoid malignancies

  2016cites this paper
• Chimeric antigen receptors: driving immunology towards synthetic biology.

  2016cites this paper
• CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas.

  2016cites this paper
• Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies.

  2016cites this paper
• 嵌合抗原受体修饰的T细胞治疗肿瘤的不良反应及相关治疗方案的研究进展

  2016cites this paper
• Chimeric antigen receptor-redirected T cells return to the bench.

  2016cites this paper
• T-cell therapies for HIV: Preclinical successes and current clinical strategies.

  2016cites this paper
• Unlocking the therapeutic and commercial potential of CAR-T technology

  2016cites this paper
• Engineering T Cells to Functionally Cure HIV-1 Infection.

  2015cites this paper
• Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

  2015cites this paper
• Designing chimeric antigen receptors to effectively and safely target tumors.

  2015cites this paper
• CAR-T: Expression, Expansion, and Clinical Applications

  2015cites this paper
• Novel Approaches to Pediatric Cancer: Immunotherapy

  2015cites this paper
• The next steps in next-gen sequencing of cancer genomes.

  2015cites this paper
• CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.

  2015cites this paper
• CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)

  2015cites this paper
• Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs.

  2015cites this paper
• Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma

  2015cites this paper
• TRUCKs: the fourth generation of CARs

  2015cites this paper
• The journey from discoveries in fundamental immunology to cancer immunotherapy.

  2015cites this paper
• Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.

  2015cites this paper
• Immunotherapy for Acute Myeloid Leukemia.

  2015cites this paper
• New cell sources for T cell engineering and adoptive immunotherapy.

  2015cites this paper
• CD19‐Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia

  2015cites this paper
• Control of leukemia relapse after allogeneic hematopoietic stem cell transplantation: integrating transplantation with genetically modified T cell therapies

  2015cites this paper
• Adolescent and young adult patients with cancer: a milieu of unique features

  2015cites this paper